feedback

Course Director

Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP

Summa Health System
Akron, Ohio
Northeast Ohio Medical University (NEOMED)
Rootstown, Ohio

Faculty

David P. Nicolau
David P. Nicolau, PharmD, FCCP, FIDSA

Center for Anti-Infective Research & Development
Hartford Hospital
Hartford, Connecticut

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CPE
Credit Amount:1.5 Credits
Release Date:2016-Aug-18
Expiration Date:2017-Aug-17
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

There are several important considerations when designing a treatment plan for serious bacterial infections, particularly those caused by multidrug-resistant (MDR) Gram-negative pathogens. Inappropriate initial therapy can have significant consequences with respect to patient morbidity, mortality, and overall costs. Therefore, antimicrobial therapy must be optimized to ensure the highest probability of achieving a successful outcome. With a variety of agents available, there is a pressing need for the implementation of contemporary, evidence-based strategies to combat serious infections caused by Gram-negative bacteria.

This activity examines evidence-based strategies to optimize treatment for serious Gram-negative bacterial infections and reviews real-world patient scenarios to elucidate the therapeutic decision-making process for such infections in the context of current data and expert recommendations.

Upon completion of this activity, participants will be able to:
  • Discuss the evolving prevalence and etiology of Gram-negative bacteria and their impact on the clinical spectrum of serious nosocomial infections
  • Assess the efficacy and safety of current and emerging antimicrobials for serious infections caused by Gram-negative bacteria
  • Integrate patient-, pathogen-, and drug-related factors into the therapeutic decision-making process for individual patients with serious Gram-negative bacterial infections

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists and pharmacists.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: August 18, 2016 - August 17, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CPE activity for any amount during the past 12 months.

Course Director and Moderator
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP
Chair, Infectious Disease Division
Summa Health System
Akron, OH
Professor, Internal Medicine
Master Teacher
Chair, Infectious Disease Section
Northeast Ohio Medical University (NEOMED)
Rootstown, Ohio

Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Nabriva Therapeutics AG.
Advisory Board for Allergan; Melinta Therapeutics, Inc.; Merck & Co., Inc.; Motif Bio Limited; Nabriva Therapeutics AG; Sensor-Kinesis Corporation; and Tetraphase Pharmaceuticals.
Consultant for Allergan; Melinta Therapeutics, Inc.; Merck & Co., Inc.; Motif Bio Limited; Nabriva Therapeutics AG; Sensor-Kinesis Corporation; and Tetraphase Pharmaceuticals.
Other Financial or Material Support from Data Safety Monitoring Board for Paratek Pharmaceuticals, Inc.
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various antibiotics/regimens for the treatment of Gram-negative bacterial infections.

Faculty
David P. Nicolau, PharmD, FCCP, FIDSA
Director, Center for Anti-Infective Research & Development
Hartford Hospital
Hartford, Connecticut

David P. Nicolau, PharmD, FCCP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan; Bayer Corporation; Merck & Co., Inc.; Pfizer Inc.; Shionogi Inc.; and Tetraphase Pharmaceuticals.
Grant/Research Support from Allergan; Bayer Corporation; Merck & Co., Inc.; Pfizer Inc.; Shionogi Inc.; and Tetraphase Pharmaceuticals.
Speakers Bureau participant with Allergan; Bayer Corporation; Merck & Co., Inc.; Pfizer Inc.; Shionogi Inc.; and Tetraphase Pharmaceuticals.
David P. Nicolau, PharmD, FCCP, FIDSA, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various antibiotics/regimens for the treatment of Gram-negative bacterial infections.

CME Reviewer
Matthew A. Goodman, MD
Attending Physician Internal Medicine
Abington Jefferson Health
Maple Glen, Pennsylvania

Matthew A. Goodman, MD, has no financial interests/relationships or affiliations in relation to this activity.

CPE Reviewer
Teresa Haile, RPh, MBA
Blue Cross Blue Shield of Kansas City
Kansas City, Missouri

Teresa Haile, RPh, MBA, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists
ACPE The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-16-010-H01-P.

Providership
This CME/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2016, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.